- ISIN
- US7291391057
- CUSIP
- 729139105
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jun 3, 2020
Highlights
- Market Cap
- $64.40M
- Enterprise Value
- $72.70M
- EPS (TTM)
- -$1.84
- Gross Profit (TTM)
- -$812.00K
- EBITDA (TTM)
- -$115.23M
- Year Range
- $1.04 - $1.95
- Target Price
- $3.00
- ROA (TTM)
- -55.88%
- ROE (TTM)
- -68.55%
- Avg. Volume (1M)
- 683K
- Avg. Volume Value (1M)
- $757.30K
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
PLRX Performance Chart
Pliant Therapeutics, Inc. (PLRX) is down 14.8% since the beginning of the year. At $1 per share, PLRX is trading 46.7% below its 52-week high of $2. Investors who bought $1,000 worth of PLRX shares 5 years ago would now be looking at an investment worth $51.
Loading charts...
Compare this symbol against anything
Returns By Period
Pliant Therapeutics, Inc. (PLRX) has returned -14.75% so far this year and -34.18% over the past 12 months.
Pliant Therapeutics, Inc.
- 1D
- -1.89%
- 1M
- -11.11%
- 6M
- -14.05%
- YTD
- -14.75%
- 1Y
- -34.18%
- 3Y*
- -60.98%
- 5Y*
- -44.75%
- 10Y*
- —
- ALL TIME*
- -40.33%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
PLRX Monthly Returns History
Based on dividend-adjusted daily data since Jun 3, 2020, PLRX's average daily return is -0.03%, while the average monthly return is -1.13%.
Historically, 34% of months were positive and 66% were negative. The best month was Jul 2022 with a return of +116.9%, while the worst month was Feb 2025 at -68.0%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 14 months.
On a daily basis, PLRX closed higher 48% of trading days. The best single day was Jul 11, 2022 with a return of +159.0%, while the worst single day was Feb 10, 2025 at -60.6%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -0.82% | 7.44% | -3.08% | -3.17% | 3.28% | -9.52% | -8.77% | -14.75% | |||||
| 2025 | -18.38% | -68.00% | -60.76% | 17.78% | -15.09% | -14.07% | 25.86% | 12.33% | -9.76% | 13.51% | -4.17% | -24.22% | -90.74% |
| 2024 | -1.05% | -11.44% | -6.11% | -20.67% | 2.62% | -11.38% | 33.12% | -7.13% | -15.65% | 25.51% | -1.92% | -4.57% | -27.28% |
| 2023 | 81.27% | -9.08% | -16.51% | 6.20% | -23.43% | -16.23% | -1.55% | -5.38% | 2.73% | -15.40% | -5.32% | 30.38% | -6.31% |
| 2022 | -13.11% | -23.53% | -21.85% | -16.41% | -3.92% | 42.27% | 116.85% | 11.00% | 8.35% | 19.05% | -26.10% | 5.17% | 43.19% |
| 2021 | 8.32% | 34.46% | 18.86% | -14.82% | -10.27% | -3.13% | -30.63% | -9.70% | -7.46% | -5.63% | -10.99% | -4.80% | -40.58% |
Benchmark Metrics
Pliant Therapeutics, Inc. has an annualized alpha of -19.54%, beta of 0.95, and R2 of 0.03 versus S&P 500 Index. Calculated based on daily prices since June 03, 2020.
- This stock participated in 211.43% of S&P 500 Index downside but only -9.59% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.03 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -19.54%
- Beta
- 0.95
- R²
- 0.03
- Upside Capture
- -9.59%
- Downside Capture
- 211.43%
Return for Risk
Risk / Return Rank
PLRX ranks 21 for risk / return — above 21% of stocks peers on PortfoliosLab. Its historical combined result is below the peer median.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Pliant Therapeutics, Inc. (PLRX) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| PLRX | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.94 | ||
| Sortino ratioReturn per unit of downside risk | -2.49 | ||
| Omega ratioGain probability vs. loss probability | 0.94 | 1.25 | -0.31 |
| Calmar ratioReturn relative to maximum drawdown | -0.65 | 2.00 | -2.65 |
| Martin ratioReturn relative to average drawdown | -0.98 | 8.49 | -9.47 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Pliant Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Pliant Therapeutics, Inc. was 97.41%, occurring on Jul 31, 2026. The portfolio has not yet recovered.
The current Pliant Therapeutics, Inc. drawdown is 97.41%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-97.41%Jul 2026 | 5y 4mo | — | 5y 4moMar 2021 - now | — |
-43.59%Oct 2020 | 3mo 3d | 4mo 26d | 7mo 29dJun 2020 - Feb 2021 | — |
-21.34%Mar 2021 | 8d | 20d | 28dFeb 2021 - Mar 2021 | — |
-14.80%Jun 2020 | 1d | 12d | 12dJun 2020 - Jun 2020 | — |
-2.53%Jun 2020 | 1d | 1d | 1dJun 2020 - Jun 2020 | — |
Drawdown Indicators
| PLRX | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.41% | -56.78% | -40.63% |
Max Drawdown (1Y)Largest decline over 1 year | -44.39% | -9.10% | -35.29% |
Max Drawdown (3Y)Largest decline over 3 years | -94.84% | -18.90% | -75.94% |
Max Drawdown (5Y)Largest decline over 5 years | -97.13% | -25.43% | -71.70% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -97.41% | -1.58% | -95.83% |
Average DrawdownAverage peak-to-trough decline | -61.37% | -10.70% | -50.67% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 29.34% | 2.14% | +27.20% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Pliant Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Pliant Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for PLRX in comparison with other companies in the Biotechnology industry. Currently, PLRX has a P/B value of 0.4. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with PLRX
Add Pliant Therapeutics, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with PLRX